Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to reduced caloric intake ...

The increasing consumption of processed foods, reduced physical activity, and lifestyle changes have further intensified the ...

Indian Council of Medical Research and NITI Aayog have said that investing in adolescent nutrition is a national imperative ...

Eli Lilly launches anti-obesity and diabetes drug Mounjaro in India, priced competitively at Rs 14,000-17,500, a fraction of ...

Investing in adolescent nutrition is a national imperative, and key to tackling the country’s rising obesity issues, said ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

The clarion call for large-scale awareness and behavior change to address the menace of obesity among children by Prime ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Overweight and obesity in adults and children have doubled in the last 15 years and tripled in the last three decades. A nationwide study by the Indian Council of Medical Research in The Lancet ...

Our preclinical studies in animal models have demonstrated promising results in reducing obesity and fatty liver disease.

The consortium, Let’s Fix Our Food, has come out with suggestions to control intake of high-fat, salt & sugar foods. Over 17 ...